

August 31, 2016

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (DE-134) NAVICIXIZUMAB
 PRONUNCIATION nav" i six iz' ue mab
 THERAPEUTIC CLAIM Treatment of cancer

CHEMICAL NAMES

1. Immunoglobulin G2, anti-(human protein DLL4 (delta-like protein 4)) (human-*Mus musculus* monoclonal OMP-305B83 heavy chain), disulfide with human-*Mus musculus* monoclonal OMP-305B83 κ-chain, dimer with immunoglobulin G2, anti-(human vascular endothelial growth factor) (human-*Mus musculus* monoclonal OMP-305B83 heavy chain), disulfide with anti-(human protein DLL4 (delta-like protein 4)) human-*Mus musculus* monoclonal OMP-305B83 κ-chain
2. Immunoglobulin G2-kappa, anti-[*Homo sapiens* DLL4 (delta-like 4)] and anti-[*Homo sapiens* VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)], humanized and chimeric monoclonal antibody, bispecific; gamma2 heavy chain, humanized anti-DLL4 (1-445) [humanized VH (*Homo sapiens* IGHV1-18*01 (84.70%) - (IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG2*01 (CH1 (120-217), hinge (218-229), CH2 (230- 338), CH3 (339-443) K26>E (368), K88>E (407), CHS (444-445)) (120-445)],(133-218')-disulfide with kappa light chain, chimeric (1'-218') [chimeric V-KAPPA (*Mus musculus* IGKV3-2*01 -*Homo sapiens* IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; gamma2 heavy chain, humanized anti-VEGFA (1-447) [humanized VH (*Homo sapiens* IGHV1-46*01 (83.30%) - (IGHD)-IGHJ4*01) [8.8.14] (1-121) -*Homo sapiens* IGHG2*01 (CH1(122-219), hinge (220-231), CH2 (232- 340), CH3 (341-445) E13>K(357), D84.2>K (399), CHS (446-447)) (122-447)], (135'-218''')-disulfide with kappa light chain, chimeric (1'''-218''') [chimeric V-KAPPA (*Mus musculus* IGKV3-2*01 -*Homo sapiens* IGKJ1*01) [10.3.9] (1'''-111''') -*Homo sapiens* IGKC*01, Km3 (112'''-218''')]; dimer (221-223":222-224":225-227":228-230")- tetrakisdisulfide

STRUCTURAL FORMULA

Anti-DLL4 heavy chain

QVQLVQSGAE	VKKPGASVKI	SCKASGYSFT	AYYIHWVKQA	PGQGLEWIGY	50
ISNYNRRATNY	NQKFKGRVTF	TTDTSTSTAY	MELRSLRSDD	TAVYYCARDY	100
DYDVGMDYWG	QGTLVTVSSA	STKGPSVFPL	APCSRSTSES	TAALGCLVKD	150
YFPEPVTVSW	NSGALTSGVH	TFFPAVLQSSG	LYSLSSVVTV	PSSNFGTQTY	200
TCNVDHKPSN	TKVDKTVRK	CCVECPPCA	PPVAGPSVFL	FPPKPKDTLM	250
ISRTPEVTCV	VVDVSHEDPE	VQFNWYVDGV	EVHNAKTKPR	EEQFNSTFRV	300
VSVLTVVHQD	WLNKEYKCK	VSNKGLPAPI	EKTISKTKGQ	PREPQVYTLP	350

PSREEMTKNQ	VSLTCLVEGF	YPSDIAVEWE	SNGQPENNYK	TPPMLDSDG	400
FFFLYSELTV	DKSRWQQGNV	FSCSVMHEAL	HNHYTQKSL	LSPGK	445

Light Chain 1

DIVMTQSPDS	LAVSLGERAT	ISCRASESVD	NYGISFMKWF	QKPGQPPKL	50'
LIYAASNQGS	GVPDRFSGSG	SGTDFTLTIS	SLQAEDVAVY	YCQKSKEVPW	100'
TFGGGTKVEI	KRTVAAPSVF	IFPPSDEQLK	SGTASVVCLL	NNFYPREAKV	150'
QWKVDNALQS	GNSQESVTEQ	DSKDYSTYSL	STLTLSKADY	EKHKVYACEV	200'
THQGLSSPVT	KSFNRGEC				218'

Anti-VEGF heavy chain

QVQLVQSGAE	VKKPGASVKV	SCKASGYTFT	NYWMHWVRQA	PGQGLEWMGD	50''
INPSNGRTSY	KEKFKRRVTL	SVDKSSSTAY	MELSSLRSED	TAVYFCTIHY	100''
DDKYYPLMDY	WQQGTLVTVS	SASTKGPSVF	PLAPCSRSTS	ESTAALGCLV	150''
KDYFPEPVTV	SWNSGALTS	VHTFPAVLQS	SGLYSLSSV	TVPSNFGTQ	200''
TYTCNVDHKP	SNTKVDKTVE	RKCCVECP	PAPPVAGPSV	FLFPPKPKDT	250''
LMISRTPEVT	CVVVDVSHED	PEVQFNWYVD	GVEVHNAKTK	PREEQFNSTF	300''
RVVSVLTVVH	QDWLNGKEYK	CKVSNKGLPA	PIEKTISKTK	GQPREPQVYT	350''
LPPSREKMTK	NQVSLTCLVK	GFYPSDIAVE	WESNGQPENN	YKTTTPMLKS	400''
DGSFFLYSKL	TVDKSRWQQG	NVDFCSVMHE	ALHNHYTQKS	LSLSPGK	447''

Light chain 2

DIVMTQSPDS	LAVSLGERAT	ISCRASESVD	NYGISFMKWF	QKPGQPPKL	50''
LIYAASNQGS	GVPDRFSGSG	SGTDFTLTIS	SLQAEDVAVY	YCQKSKEVPW	100''
TFGGGTKVEI	KRTVAAPSVF	IFPPSDEQLK	SGTASVVCLL	NNFYPREAKV	150''
QWKVDNALQS	GNSQESVTEQ	DSKDYSTYSL	STLTLSKADY	EKHKVYACEV	200''
THQGLSSPVT	KSFNRGEC				218''

Disulfide bridges

Intrachain Disulfide bridges

22-96	22''-96''	23'-92'	23'''-92'''	138'-198'	138'''-198'''
146-202	148''-204''	259-319	261''-321''	365-423	367''-425''

Interchain Disulfide bridges

Type A crosslinks

133-218'	135''-218'''	221-223''	222-224''	225-227''	228-230''
----------	--------------	-----------	-----------	-----------	-----------

Type B crosslinks

133-224''	222-135''	221-218'	223'''-218'''	225-227''	228-230''
-----------	-----------	----------	---------------	-----------	-----------

Type A/B Crosslinks

133-223''	135''-218'''	221-218'	222-224''	225-227''	228-230''
-----------	--------------	----------	-----------	-----------	-----------

or

133-218'	135''-221	223'''-218'''	22-224''	225-227''	228-230''
----------	-----------	---------------	----------	-----------	-----------

Glycosylation sites (N)

Asn-295 Asn-297''

MOLECULAR FORMULA

C₆₄₈₁H₉₉₈₁N₁₇₁₉O₂₀₃₀S₅₄

MOLECULAR WEIGHT

145.9 kDa

TRADEMARK

None as yet

SPONSOR

OncoMed Pharmaceuticals Inc.

CODE DESIGNATIONS

OMP-305B83

CAS REGISTRY NUMBER

1638338-43-8

UNII 1W14T9L25W

WHO NUMBER 10220

gbk